Health & Fitness
Health and Fitness
Health and Fitness
Tue, February 28, 2012Mon, February 27, 2012Sat, February 25, 2012Fri, February 24, 2012Thu, February 23, 2012Wed, February 22, 2012Tue, February 21, 2012Mon, February 20, 2012Sat, February 18, 2012Fri, February 17, 2012Thu, February 16, 2012Wed, February 15, 2012SciClone Pharmaceuticals to Present at RBC Capital Markets' Global Healthcare Conference
Published in Health and Fitness on Wednesday, February 22nd 2012 at 4:07 GMT by Market Wire
February 22, 2012 07:00 ET
SciClone Pharmaceuticals to Present at RBC Capital Markets' Global Healthcare Conference
FOSTER CITY, CA--(Marketwire - Feb 22, 2012) - SciClone Pharmaceuticals, Inc. (
To access the live audio webcast of the presentation, please log on through a link located in the Investor Relations section of SciClone's website at [ www.sciclone.com ], under the Calendar of Events tab. A replay of the webcast will be available one hour after the conclusion of the live event.
About SciClone
SciClone Pharmaceuticals is a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. Besides ZADAXIN, SciClone markets nearly 20 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also developing SCV-07 in a phase 2b trial for the delay to onset of oral mucositis in patients with head and neck cancer. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit [ www.sciclone.com ].
Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi.
Aggrastat is a registered trademark of Merck & Co., Inc.
